Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (151-160 of 346) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|July 24, 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib eraFadi G Haddad, Koji Sasaki, Aram Bidikian, et al.
The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood Cancer Journal|November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guideWei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic LeukemiaNicholas J Short, Elias Jabbour, Trevor Jamison, et al.
American Journal of Hematology|October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapyKoji Sasaki, Tapan Kadia, Kebede Begna, et al.
Blood Cancer Journal|August 7, 2024
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicinJayastu Senapati, Elias Jabbour, Nicholas J Short, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
American Journal of Hematology|April 13, 2019
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blastsPaolo Strati, Guillermo Garcia-Manero, Chong Zhao, et al.
British Journal of Haematology|June 16, 2017
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.
Pageof 35

Showing results (151-160 of 346) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|July 24, 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib eraFadi G Haddad, Koji Sasaki, Aram Bidikian, et al.
The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood Cancer Journal|November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guideWei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic LeukemiaNicholas J Short, Elias Jabbour, Trevor Jamison, et al.
American Journal of Hematology|October 30, 2021
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapyKoji Sasaki, Tapan Kadia, Kebede Begna, et al.
Blood Cancer Journal|August 7, 2024
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicinJayastu Senapati, Elias Jabbour, Nicholas J Short, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
American Journal of Hematology|April 13, 2019
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blastsPaolo Strati, Guillermo Garcia-Manero, Chong Zhao, et al.
British Journal of Haematology|June 16, 2017
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.
Pageof 35